MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Net Income
-$1,941,558
EPS
-$0.18
Unit: Dollar
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-03-31
2025-12-31
2025-09-30
2025-06-30
Revenues
-
-
-
0
General and administrative costs
1,654,031
1,772,400
1,750,658
714,161
Research and development costs
333,376
52,118
50,696
60,648
Total costs and expenses
1,987,407
1,824,518
1,801,354
774,809
Loss from operations
-1,987,407
-1,824,518
-1,801,354
-774,809
Interest income
3,370
2,152
4,430
365
Interest expense
3,096
3,756
457
1,810
Unrealized gain (loss) on digital assets
-
-
-182,887
-
Realized loss on digital assets
-
568,521*
-
-
Foreign currency gain (loss)
-475
915*
-130
-
Other income
-
935*
-
-
Foreign currency gain
-
-
-
581
Net loss
-1,987,608
-2,392,793*
-
-
Net loss attributable to common stockholders
-
-2,612,967
-1,980,398
-775,673
Series b convertible preferred stock 8 cumulative dividend
-17,882
220,174*
-50,367
-
Non-controlling interest
-63,932
-
-
-
Net loss attributable to common stockholders
-1,941,558
-
-2,030,765
-
Basic EPS
-0.18
-
-0.33
-0.29
Diluted EPS
-0.18
-0.529
-0.33
-0.29
Basic Average Shares
10,889,003
-
6,171,195
2,720,533
Diluted Average Shares
10,889,003
4,840,731*
6,171,195
2,720,533
Page 1
Unit: Dollar. Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
Net loss
attributable to common...
-$1,941,558
Non-controlling interest
-$63,932
Net loss
-$1,987,608
(-180.12%↓ Y/Y)
Interest income
$3,370
(664.17%↑ Y/Y)
Series b convertible
preferred stock 8...
-$17,882
Loss from operations
-$1,987,407
(-181.13%↓ Y/Y)
Interest expense
$3,096
(-1.24%↓ Y/Y)
Foreign currency gain
(loss)
-$475
Total costs and
expenses
$1,987,407
(181.13%↑ Y/Y)
General and
administrative costs
$1,654,031
(168.74%↑ Y/Y)
Research and development
costs
$333,376
(264.52%↑ Y/Y)
Buy us a coffee
LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXT)
LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXT)